ESMO 2023

5 year follow-up

Preoperative checkpointinihition in ER+ disease

Highlights in eBC

Remarkable efficacies in patients with HER2+ mBC with brain metastases

My highlights of ESMO23 in metastatic breast cancer

DATO-DX - where is it going?

The FGFR story in bladder cancer at ESMO23

Clearing up non-clear cell RCC

New 3rd line therapy for RCC

Lu-PSMA leads forward

Early use of enzalutamide in advanced prostate cancer

When the history of ADC is written: Redefining first-line standard of care in mUC!

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

ALINA - immediate change of practice!

My highlights from ESMO 2023

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Tarlatamab in SCLC

What is your definition of triple-negative breast cancer?

Data updates for CDK4/6 inhibitors in EBC at ESMO23 - implications for clinical practice

What was the most exciting news at ESMO23?

Anticipated updates and exciting new data for checkpointinhibitors

New and better biomarkers are needed!

Analysis of tumour microenvironment and immunophenotype in TNBC

Prognostic score in early HR+/HER2-BC: translational data from ADAPT

Carry-over effects in monarchE confirmed

Our guidelines are correct

ER-low corresponds diagnostically to ER-0 breast cancer

Consolidation of data in early HR+ and triple-negative breast cancer

Ribociclib effective in all subtypes

Preoperative checkpointinihition in ER+ disease

Pembrolizumab solidifies as SOC in early-stage TNBC

HR+ study with > 20 % PCR

My highlights of ESMO23 in early breast cancer

Clinically relevant effect of pembro also in PCR

Neoadjuvant IO - is their new strategy in HR+ breast cancer

Metabolomics reveal differential expression of OMEGA 3 & OMEGA 6 in neoadjuvant treatment

Highlights in eBC

New data on neoadjuvant immunotherapy

Negative EFS results from NeoTrip

Immunoncology in eBC - triple negative and more?

MonarchE - trial update

5 year follow-up

Use of immunotherapy in the perioperative setting of luminal Her2- BC

Detailed view of nodal-negative patients

MonarchE - mise à jour de l'essai

Studio NeoTrip: negativi i risultati

Punti salienti in eBC

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6 nel condizionare la risposta alla terapia neo-adiuvante

Nouvelles données sur l'immunothérapie néoadjuvante

New ADC for metastatic breast cancer?

New targets, new linker, new ADCs - much more to learn with new therapies!

ADCs in HER2+, HER2low and TNBC - what is the future of ADCs?

Improvement of therapy outcome by app-based patient education

What was the most exciting news at ESMO23?

How to organize a molecular tumorboards in breast cancer?

Dato-DXd - new player in advanced luminal disease

T-DXd in HER2+ patients with brain metastases

OP seems to be dispensable for super responders

Still on track for success in HER2-low MBC

T-DXd also effective for brain metastases

Abemaciclib remains consistent in 5-year follow-up

Can surgery be spared following primary systemic therapy?

DATO-DX - where is it going?

My highlights of ESMO23 in metastatic breast cancer

TROP2 expression as a potential mechanism of resistance in HER2+ patients

HER2DX in the PHERgain trial

Remarkable efficacies in patients with HER2+ mBC with brain metastases

Fulvestran better than anastrozole, but no survival benefit

HS20089 - a novel ADC is coming for TNBC

TULIP: Trastuzumab duocarmazine without OS benefit

Robust data from the monarchE

ADC + Immunotherapy - the BEGONIA study paradigm

Duvalumab + Dato-DXd effective

Our guidelines are correct

Even more new generation ADCs in breast cancer?

Highlights in mBC

T-DXd - new standard of care for brain mets?

OP-1250 (Palezestrant) confirms the role of SIRDs after CDK4/6i

Benefit for SG even after intensive pretreatment

Improved oncological therapy with the smartphone

New ADC in HR+ disease

Patient-centered molecular medicine - a new approach

T-DXd - nowy standard postępowania w przerzutach do mózgu?

HER2DX en el estudio PHERgain

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei SERDs dopo le cicline

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym leczeniu systemowym?

Lo studio BEGONIA nelle paziento con tumore triplo negativo

HS20089 - un nuovo ADC che si affaccia sulla scenda del TNBC

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

La expresión de TROP2 como potencial mecanismo de resistencia en pacientes HER2+.

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par le cancer triple negative

Punti salienti in mBC

What is the future of immune therapy in prostate cancer?

Targeted therapy will move forward - but more robust data is needed.

The optimal timing of RT after radical prostatectomy and QoL data of ENZA therapy in nmHSPC

Should we use zoledronic acid in all ADT patients?

Early use of enzalutamide in advanced prostate cancer

When immunotherapy is probably not the best choice: The case of untreated metastatic prostate cancer

Precision medicine at mCRCP

STAMPEDE. Bone prediction not for everyone - better risk stratification for PCa

Immunotherapy in metastatic PCa

Longterm toxicity of adjuvant RT after prostatectomy

Salvage radiotherapy the new standard

CXCR2 inhibitor in PCa

Brave New World in mCRPC

EMBARK expands ENZA indication to PCa

Lu-PSMA leads forward

Big data and AI prediction tools

PSMA FORE: Trial and controversies

EMBARK - Quality of Life

PSMAfore unleashes urooncologic opportunity

Combination of radioligand therapy with chemotherapy useful

Osteoprotection at mHSPC

Embark without fear

Negative data for pembrolizumab in mHSCPC & mCRPC

TITAN: ultra-low PSA = best prognosis

ENZA P:Trial and controversies

IO therapy in metastatic prostate cancer.

RADICALS RT: Trial and controversies

STAMPEDE data. Skelettstärkande och riskstratifiering.

Immunterapi vid prostatacancer

Big Data och AI för prediktion vid prostatacancer

EMBARK och livskvalitet

Cuando la inmunoterapia probablemente no es la mejor elección: El caso del cancer de próstata avanzado en pacientes no seleccionados

CXCR2 hämmare och prostatacancer

FGFR inhibitors and ADC combinations in urothelial cancer - new options for the future?!

Part 2: New standard of care in first line urothelial cancer!

Part1: New standard of care in first line urothelial cancer?!

Unique bladder delivery system of gemcitabine herolds remarkable response

The FGFR story in bladder cancer at ESMO23

When the history of ADC is written: Redefining first-line standard of care in mUC!

DAD, DAD-IO

EV + Pembro as standard of care in first-line therapy of bladder cancer

Amazing new data in bladder cancer

New SoC in firstline bladder cancer

FGFR inhibitors: What is the best scenario for this family of compounds?

Chemo-IO establishes itself in the first-line treatment of bladder cancer

Inhibidores de FGFR: Cual es el mejor escenario para esta familia de fármacos?

Στιγμιότυπα για τον καρκίνο των νεφρών και της ουροδόχου κύστης στο ESMO23

L'histoire du FGFR dans le cancer de la vessie à l'ESMO23

Reescribiendo la historia de una enfermedad: Nuevo estándar de tratamiento en primera linea en cancer urotelial avanzado

Important new treatment option but only for subset of patients?

Where does the future therapy go in renal cell carcinoma?

Is de-escalating therapy ready for prime-time?

New 3rd line therapy for RCC

Intermittent therapy also possible with TKIs

Clearing up non-clear cell RCC

New mode of action in mRCC - ready for prime time?

Belzutifan - whats next kidney cancer?

Belzutifan in later lines of therapy

Kidney cancer highlights at ESMO23

Moving patients to the neoadjuvant setting in non-metastatic NSCLC

ALINA - remarkably positive DFS in early-stage ALK+ NSCLC

Circulating DNA in AEGEAN trial

ALINA - a new paradigm in operated NSCLC with ALK-fusion

Scene is set for inductive immunotherapy

Perioperative IO: OS-benefi from KEYNOTE-671

ALINA - immediate change of practice!

Big improvements in early stage and a subset of metatstic NSCLC

My highlights from ESMO 2023

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Substantial improvement in local regional NSCLC

Neoadjuvant chemo-immunotherapy new standards in early & advanced NSCLC

Adjuvant alectinib in patients with early-stage ALK+ NSCLC

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

I miei punti salienti di ESMO 2023

ALINA - un nouveau paradigme dans cBNPC avec la fusion ALK

Perioperatieve chemo-immunotherapie voor alle patienten met resectabel stadium II-IIIB NSCLC?

Les points forts de l'ESMO 2023

Rare oncogenic alterations: landmark results on exon 20 insertion & confirming data on RET fusion+ NSCLC

Activating EGFR-mutation - what's coming up?

Evolving landscape of ADCs

ESMO2023-impact on everyday practice!

Substantial improvement in rare alterations

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

MARIPOSA: Trial and controversies

MARIPOSA II: Trial and controversies

NRG fusions: a new drugable target?

Treatment sequences for EGFR-mutated Patients

TROPION-Lung01: positive development

LIBRETO - a positive study, but was it necessary?

PAPILLON - bringing together therapy for the 1st line

My highlights from ESMO 2023

Amivantamab at progression? MARIPOSA-2 trial

Does immunotherapy still have a place in EGFR-positive mNSCLC?

New standard of care for metastatic EGFR exon 20 insertion mutated NSCLC

Amivantamab upfront? MARIPOSA trial

Do ADCs have brain activity?

Adagrasib + pembrolizumab in patients with KRASG12C mutation

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Changing treatment landscape in EGFR-mutated NSCLC

Practice changing results on exon 20 insertion mNSCLC

Brain metastases – options to improve the systemic treatment

Big improvements in early stage and a subset of metatstic NSCLC

By unanimous decision and still the champion – docetaxel!

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

Quelles séquences thérapeutiques pour les patients EGFR mutés

I miei punti salienti di ESMO 2023

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Nieuwe standaard voor gemetastaseerd EGFR exon20 insertie gemuteerd NSCLC

Heeft immunotherapie nog een plek in de behandeling van EGFR-positief gemetastaseerd NSCLC?

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

L’amivantamab, nouveau standard de traitement pour les EGFR exon 20

Veränderte Behandlungslandschaft bei EGFR-mutiertem NSCLC

Amivantamab at progression? MARIPOSA-2 trial

Amivantamab upfront? MARIPOSA trial

Les points forts de l'ESMO 2023

Impact of T-cell engagers in SCLC

A new option in relapsed SCLC

New hope for patients with SCLC

Tarlatamab in SCLC

Neue Hoffnung für Patienten mit SCLC

Update on gynaecological cancers

New data on H&N Cancer

New data on sarkomas

PCO Therapeutics

Precision oncology in CUP

First data on luveltamab in multiline treatment for endometrial cancer

Evolution of the revolution - the RUBY trial